Clinical Trials Browser

Phase 2 × UNKNOWN × Interventional × Clear all

Breast Neoplasms

Triple Negative Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Colonic Neoplasms

Stomach Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Carcinoma, Transitional Cell

HER2-positive

Platinum-resistant Recurrent Ovarian Cancer

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Colorectal Neoplasms

Lymphoma, Extranodal NK-T-Cell

Stomach Neoplasms

Squamous Cell Carcinoma of Head and Neck, Nausea, Radiation Injuries, Vomiting

Triple Negative Breast Neoplasms

HER2-positive Breast Cancer

Lymphoma, Extranodal NK-T-Cell

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

Rectal Neoplasms

Advanced Breast Cancer

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Lymphoma, Recurrence

Triple Negative Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Rectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Esophageal Neoplasms

Stomach Neoplasms

Hypopharyngeal Neoplasms

Colorectal Neoplasms

Stomach Neoplasms

Small Cell Lung Carcinoma

Ovarian Neoplasms

Breast Neoplasms

Small Cell Lung Carcinoma

Breast Neoplasms

Nasopharyngeal Carcinoma

Head and Neck Neoplasms, Vomiting

HER2-positive Breast Cancer

Hormone Receptor Positive Advanced Breast Cancer

Triple Negative Breast Neoplasms

Lymphoma, Large B-Cell, Diffuse

Esophageal Squamous Cell Carcinoma

Breast Neoplasms

Stomach Neoplasms

Esophageal Neoplasms

Breast Neoplasms

Head and Neck Squamous Cell Cancer

Clinical Trials

HGWD Improve the Paclitaxel-related Neurotoxicity in Patients With BC

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

MATCH

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

APPROVE

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer

The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

LM-HNSCC

Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Anlotinib in Metastatic HER2 Negative Breast Cancer

The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma

Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma

Pyrotinib

HNSCC